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Abstract
Introduction: The organisation of the mammary epithelial hierarchy is poorly understood. Our hypothesis is that
the luminal cell compartment is more complex than initially described, and that an understanding of the
developmental relationships within this lineage will help in understanding the cellular context in which breast
tumours occur.
Methods: We used fluorescence-activated cell sorting along with in vitro and in vivo functional assays to examine
the growth and differentiation properties of distinct subsets of human and mouse mammary epithelial cells. We
also examined how loss of steroid hormones influenced these populations in vivo. Gene expression profiles were
also obtained for all the purified cell populations and correlated to those obtained from breast tumours.
Results: The luminal cell compartment of the mouse mammary gland can be resolved into nonclonogenic
oestrogen receptor-positive (ER+) luminal cells, ER+ luminal progenitors and oestrogen receptor-negative (ER-)
luminal progenitors. The ER+ luminal progenitors are unique in regard to cell survival, as they are relatively
insensitive to loss of oestrogen and progesterone when compared with the other types of mammary epithelial
cells. Analysis of normal human breast tissue reveals a similar hierarchical organisation composed of nonclonogenic
luminal cells, and relatively differentiated (EpCAM+CD49f+ALDH-) and undifferentiated (EpCAM+CD49f+ALDH+)
luminal progenitors. In addition, approximately one-quarter of human breast samples examined contained an
additional population that had a distinct luminal progenitor phenotype, characterised by low expression of ERBB3
and low proliferative potential. Parent-progeny relationship experiments demonstrated that all luminal progenitor
populations in both species are highly plastic and, at low frequencies, can generate progeny representing all
mammary cell types. The ER- luminal progenitors in the mouse and the ALDH+ luminal progenitors in the human
appear to be analogous populations since they both have gene signatures that are associated with alveolar
differentiation and resemble those obtained from basal-like breast tumours.
Conclusion: The luminal cell compartment in the mammary epithelium is more heterogeneous than initially
perceived since progenitors of varying levels of luminal cell differentiation and proliferative capacities can be
identified. An understanding of these cells will be essential for understanding the origins and the cellular context
of human breast tumours.
Introduction
Human breast tumours are very heterogeneous, with
approximately five molecular subtypes recognised; these
molecular subtypes are categorised as Luminal A, Lumi-
nal B, claudinlow, basal-like and Her2 [1-3]. Currently
unknown is whether breast tumours have a common
cell of origin or whether different types of tumours ori-
ginate from different types of cells, or whether it is a
combination of these two processes [4]. Support for the
second hypothesis comes from studies in which different
populations of human breast epithelial cells were
selected from in vitro cultures or were purified using
flow cytometry and reverse-engineered into tumours of
distinct subtypes using lentiviral vectors [5,6]. Similar
results have been observed in a mouse model where loss
of Brca1 in different epithelial cell compartments
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resulted in tumours with different histologies [7]. An
understanding of the properties of the normal mammary
epithelial cell hierarchy will thus be important in under-
standing the cellular context in which human breast
tumours occur. Similarly, an understanding of this hier-
archy may also give insight into the properties of cancer
stem cells and the behaviour of tumours during the
emergence of therapeutic resistance.
The mammary epithelium has traditionally been
described as a bilineage epithelium composed of luminal
cells and basally-positioned myoepithelial cells that are
collectively organised in a series of ducts that drain
lobuloalveolar structures during lactation. Previous stu-
dies have demonstrated that mammary stem cells have
features characteristic of basal cells, whereas the bulk of
the progenitor cells display predominantly luminal fea-
tures and have luminal-restricted development potential
[8,9], although a recent report has demonstrated that a
separate stem/progenitor cell maintains each lineage
during adult tissue homeostasis [10]. The luminal cell
compartment is heterogeneous since only a subset of
these cells expresses oestrogen receptor (ER) [11]. Most
of these ER+ cells are perceived to be relatively mature
cells since they are rarely observed to be cycling in adult
mammary tissue [12,13]. However, rare proliferating ER+
cells can be detected in the mouse mammary gland,
suggesting the existence of an ER+ progenitor cell [14].
More recently, fluorescence-activated cell sorting has
been used to prospectively isolate luminal progenitors
(LPs) from the mouse mammary gland based on differ-
ential expression of c-Kit and CD14 or c-Kit and Sca1
[15,16]. This latter study was able to identify a subpopu-
lation of cells with a Sca1+c-Kit+ phenotype that was
enriched for ER+ LP cells [15]. Similarly, an ER- LP cell
that has a CD24highSca1-c-Kit+ phenotype can also be
identified [15,17]. These cells appear to function as
alveolar progenitor cells and are characterised by high
expression of the transcription factor Elf5 [18].
To further characterise the cells that make up the
luminal cell hierarchy in both the human and mouse
mammary glands, we used a combination of fluores-
cence-activated cell sorting, in vitro and in vivo func-
tional assays and gene expression profiling strategies.
Our results describe the prospective isolation and func-
tional characterisation of discrete ER+ and ER- LP popu-
lations that are present in both species. Our results also
demonstrate that both of these populations are develop-
mentally plastic and display multilineage potential, and
that the ER+ LPs, at least in the mouse, have a relative
survival advantage in a low oestrogen/progesterone
environment. We also identify a novel breast cell type in
the human mammary epithelium that is characterised
by low expression of ERBB3.
Materials and methods
Dissociation of human and mouse mammary tissue
All primary human material was derived from 11 reduc-
tion mammoplasties at Addenbrooke’s Hospital, Cam-
bridge, UK, under full informed consent and in
accordance with the National Research Ethics Service,
Cambridgeshire 2 Research Ethics Committee approval
(08/H0308/178) as part of the Adult Breast Stem Cell
Study. All tissue donors had no previous history of can-
cer and were premenopausal (ages 18 to 46). Mammary
tissue was dissociated to single cell suspensions as pre-
viously described [19].
The number 3 and/or number 4 mammary glands
were dissected from 10-week-old to 14-week-old virgin
or 20-day pregnant female C57BL6/J, C57BL6/J.CBA-Tg
(ACTbEGFP) and FVB mice and were dissociated in
DMEM/F12 (with 2.5 mM L-glutamine and 15 mM
HEPES; Gibco, Paisley, Renfrewshire, UK) supplemented
with 1 mg/ml collagenase (Roche, Burgess Hill, West
Sussex, UK), 100 U/ml hyaluronidase (Sigma, Poole,
Dorset, UK) and 50 μg/ml gentamicin (Gibco) for 14 to
16 hours at 37°C. The mammary glands were then pro-
cessed to single cells as previously described [8]. In
some experiments, 8-week-old C57BL/6J mice were
ovariectomised or sham-operated 3 weeks prior to col-
lection of mammary tissue.
Flow cytometry
Single cell suspensions of human mammary cells were
treated to detect the enzyme activity of aldehyde dehy-
drogenase (ALDH) using the Aldefluor Kit (StemCell
Technologies, Grenoble, Rhône-Alpes, France) as per
the manufacturer’s instructions. The cells were then pre-
blocked with 10% normal rat serum (Sigma) and incu-
bated with the following primary antibodies (Table S1 in
Additional file 1): CD31-PE/Cy7, CD45-PE/Cy7, epithe-
lial cell adhesion molecule (EpCAM)-PE, CD49f-Alexa
Fluor (AF) 647 or CD49f-Pacific Blue, ERBB3-biotin,
CD44-AF647, MUC1-AF647, and CD24-AF647. Hank’s
balanced salt solution supplemented with 2% FBS
(Gibco) was used as the diluent for all preblock, anti-
body incubation and washing steps.
Mouse mammary cells were preblocked with 10% nor-
mal rat serum and then incubated with the following
primary antibodies (Table S1 in Additional file 1):
CD31-biotin, CD45-biotin, Ter119-biotin, BP-1-biotin,
EpCAM-AF647, CD49f-AF488, or CD49f-Pacific Blue,
CD49b-PE and Sca1-PE/Cy7. CD45, Ter119, CD31 and
BP-1 were used to deplete contaminating haematopoie-
tic cells, endothelial cells and a proportion of stromal
cells, respectively (collectively termed Lin+ cells). Where
required, single cell suspensions of mouse mammary
cells were treated to detect the enzyme activity of
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ALDH using the Aldefluor Kit as per the manufacturer’s
instructions, and then cells were stained as above.
Biotin-conjugated antibodies were detected with strep-
tavidin-APC-Cy7 (BioLegend, Bar Hill, Cambridgeshire,
UK). Cells were then filtered through a 30 μm cell strai-
ner and incubated with 4’,6-diamidino-2-phenylindole
(Invitrogen, Paisley, Renfrewshire, UK) or propidium
iodide (Sigma). Human cells were sorted using an Influx
(Becton Dickinson, Oxford, Oxfordshire, UK) and
mouse cells were analysed using an LSRII (Becton Dick-
inson) and they were sorted on a FACSAria I (Becton
Dickinson) or a MoFlo (Beckman Coulter, High
Wycombe, Buckinghamshire, UK). The gating cascade is
shown in Additional file 2. A cell recovery count was
performed after each sort. Single-stained control cells
were used to perform compensation manually. Gates
were set in reference to negative controls stained with
isotype antibodies conjugated to individual fluoro-
chromes or to fluorescence-minus-one controls (omit-
ting one reagent at a time). The ALDH+ gate was set in
reference to control populations incubated with the
ALDH inhibitor DEAB in addition to Aldefluor. Flow
cytometry data were analysed using FlowJo™ software
(Tree Star, Inc., Ashland, OR, USA).
Renal grafting and mouse mammary repopulating unit
assays
All animal work was approved by Cambridge Research
Institute Animal Ethics Committee and the Home
Office. Renal capsule experiments were carried out on
10-week-old female NOD/SCID IL2Rgc-/- (NSG) mice as
previously described [19] with the modification that in
some experiments the collagen gels were supplemented
with 20% growth factor-reduced Matrigel (BD Bios-
ciences, Oxford, Oxfordshire, UK). A sialastic pellet con-
taining 2 mg 17b-oestradiol and 4 mg progesterone was
implanted subcutaneously in recipient mice when
human cells were being transplanted [20]. In some
experiments, the hormone pellets were surgically excised
5 weeks post surgery and the mice mated. To recover
renal gels, recipient mice were killed and the retrieved
gels were fixed in 4% paraformaldehyde for 1 hour
before being processed into paraffin. On occasion, gels
were dissociated for 4 to 5 hours at 37°C in Mouse Epi-
Cult-B™ media (StemCell Technologies) supplemented
with 5% FBS, 600 U/ml collagenase and 200 U/ml hya-
luronidase. After digestion, cells were washed in Hank’s
balanced salt solution supplemented with 2% FBS, tryp-
sinised for 5 minutes with gentle pipetting and injected
into the cleared mammary fat pads of NSG mice as
described below.
For the mouse mammary repopulating unit (MRU)
assays, donor cells were suspended in 65% Hank’s
balanced salt solution supplemented with 2% FBS
additionally supplemented with 25% growth factor-
reduced Matrigel and 10% trypan blue solution (0.4%;
Sigma), such that a 10 μl injection volume contained the
desired cell dose. The endogenous mammary epithelium
in the inguinal glands of 3-week-old female C57BL6/J or
NSG mice was cleared and cells were injected into
cleared fat pads as previously described [21]. The mice
were mated 3 weeks after surgery and the number 4
glands were removed during pregnancy and fixed in
Carnoys fixative and stained with carmine alum. An out-
growth was scored positive if it contained both lobular
and ductal elements. MRU frequencies were calculated
using the Extreme Limiting Dilution Analysis tool [22]).
In some experiments, mice were kept in a virgin state
for a total of 10 weeks and the number 4 glands
removed for analysis by flow cytometry or histology.
In vitro colony-forming assays
Flow-sorted human mammary cells were seeded into 60
mm plates with 2.5 × 105 irradiated NIH-3T3 feeder
cells. The cultures were maintained in Human EpiCult-
B (StemCell Technologies) supplemented with 5% FBS
(StemCell Technologies) and 50 μg/ml gentamicin for
24 to 48 hours and then the media changed to serum-
free conditions and maintained for an additional 10 to
12 days. Flow-sorted mouse cells were cultured in
Mouse EpiCult-B and 50 μg/ml gentamicin in the pre-
sence of irradiated feeders for 5 to 7 days. At the end of
the assays, the colonies were fixed with acetone:metha-
nol (1:1), stained with Giemsa (Fisher Scientific, Cram-
lington, Northumberland, UK) and enumerated under a
microscope.
In some experiments, the sorted cells were seeded
within growth factor-reduced Matrigel and cultured in
the presence of Human or Mouse EpiCult-B and irra-
diated feeders for 14 to 21 days. In some experiments,
the culture media were changed after 7 days into differ-
entiation media (DMEM/F12 with Glutamax (Gibco)
supplemented with 10% FCS, 1 μM dexamethasone, 5
μg/ml insulin and 5 μg/ml prolactin) to induce lacto-
genic differentiation of the mammary cells, and the cul-
tures were maintained for a further 7 to 14 days. At the
end of the assay, the gels were then fixed in 4% parafor-
maldehyde and embedded in paraffin for sectioning and
immunostaining.
Immunofluorescence and immunohistochemistry
Sorted cells were allowed to adhere to μ-Slide eight-well
chamber poly-lysine-coated slides (Ibidi, Uddingston
Glasgow, UK) for 15 minutes before fixation in 4% par-
aformaldehyde. Cells were blocked in 10% normal goat
serum (Sigma) for 1 hour and stained with primary anti-
bodies (Table S1 in Additional file 1) overnight at 4°C.
Goat anti-mouse or anti-rabbit antibody conjugated to
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either AF488 or AF555 (Invitrogen) was used to detect
primary antibodies. IgG antibodies at the same concen-
tration as the primaries were used as isotype controls.
Slides were stained with 4’,6-diamidino-2-phenylindole
to visualise the nuclei. Paraffin-embedded renal gels and
Matrigel cultures were sectioned at 4 μm, deparaffinised
and boiled in pH 6.0 citrate buffer. The sections were
stained as above. Where required, a Mouse on Mouse
(Vector Labs, Peterborough, Cambridgeshire, UK) pre-
blocking kit was used as per the manufacturer’s
instructions.
RNA preparation, quantitative RT-PCR analysis
Freshly sorted cells were pelleted and the supernatant
removed. RNA was extracted using the PicoPure™ RNA
extraction kit (Applied Biosystems, Paisley, Renfrew-
shire, UK) as per the manufacturer’s instructions, and
samples were treated with DNase using the RNase-free
DNase Set (Qiagen, Crawley, West Sussex, UK). For
mouse quantitative RT-PCR analysis, RNA from sorted
cells of five independent experiments was collected. For
human quantitative RT-PCR analysis, RNA from sorted
cells of six different human breast specimens was col-
lected. cDNA was generated using 100 ng RNA and ran-
dom hexamers in a 20 μl reaction using SuperScript III
(Invitrogen) according to the manufacturer’s instruc-
tions. cDNA was diluted 1/10 and 1 μl was used in a 10
μl volume reaction with 2× SYBR Green Fast PCR Mas-
ter Mix (Applied Biosciences) and 1 μl of 5 μM forward
and reverse primers (Table S2 in Additional file 1) and
H2O. The real-time PCR reactions for each sample were
performed in triplicate with an ABI 7900 Real Time
PCR system under the following conditions: 95°C for 20
seconds followed by 40 cycles of 95°C for 1 second and
60°C for 20 seconds, followed by a dissociation run to
obtain melt profiles of the amplicons. A no-template
control (no cDNA) was used as a control for all primers,
also performed in triplicate. Results were analysed with
the delta-delta method normalised to two housekeeping
genes (Ppia and Rpl13a or UBC and TBP for mouse and
human samples, respectively) and compared with a com-
parator sample (nonclonogenic luminal (NCL) cells).
Microarrays
Total RNA was purified from freshly sorted cell popula-
tions using the PicoPure™ RNA extraction kit. Up to
250 ng RNA was labelled according to the standard Illu-
mina gene expression array protocols with the Ambion
TotalPrep 96 kit (4397949; Ambion, Paisley, Renfrew-
shire, UK). Biotinylated complementary RNA was qual-
ity controlled using Agilent Bioanalyser and quantified
by spectrophotometry (Nanodrop, Ringmer, East Sussex,
UK), and 750 ng cRNA was hybridised to Illumina
Mouse6 or HumanHT12v4 BeadChips and washed,
stained and scanned according to the standard protocol
(WGGX DirectHyb Assay Guide 11286331 RevA; Illu-
mina, Saffron Walden, Essex, UK). Arrays were scanned
on an Illumina BeadArray scanner, and data were pro-
cessed using the Bioconductor beadarray package [23].
(Further information can be found in Additional file 3.)
All data files can be accessed via the Gene Expression
Omnibus [GEO:GSE35399].
Correlation of normal cell subpopulations with breast
cancer datasets
Centroid construction
Centroids of gene expression for each cell subpopulation
were built from the union set of top differentially
expressed genes between each pair of cell subtypes. To
identify differentially expressed genes we first filtered
genes according to variability and then used the limma
R package to rank them according to differential expres-
sion using B statistics. The False Discovery Rate was
estimated using the q-value R package. To avoid skew-
ing the number of centroid genes to specific cell types,
we selected the top 250 upregulated and top 250 down-
regulated genes in each cell-type comparison. All of
these passed False Discovery Rate corrected P < 0.05.
Since the three LP subpopulations were more similar to
each other than to any of the other cell types, the corre-
sponding centroids were constructed by the union set of
the top 100 upregulated and downregulated genes for
each of the three pairwise comparisons. A centroid for
the whole LP population (including the three LP subpo-
pulations) was also constructed. Finally, for each cell
type the centroid was constructed by averaging the
expression of each gene across the samples belonging to
that cell type.
Correlation scores
Having constructed the cell-type-specific centroids, we
next assessed their correlations to breast cancer profiles.
First, each breast tumour profile was classified into one
of the five intrinsic subtypes using the SSP predictor of
Hu and colleagues [24] or the claudinlow subtype
assigned by Herschkowitz and colleagues [25]. Second,
each tumour gene expression profile was correlated to
each of the centroids using a linear regression. Centroid
profiles as well as tumour profiles were scaled to unit
variance in order to ensure that regression coefficients,
which reflect Pearson correlations, are comparable.
Since each tumour can be thought of as a potential mix-
ture of transformed cells from the different normal cell
subpopulations, we also modelled each tumour profile
as an explicit mixture of the normal cell centroids using
a multivariate regression framework. In this framework,
each regression coefficient represents a partial correla-
tion and reflects the strength of association between the
tumour profile and a given cell-type centroid after
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taking into account the contributions from the other cell
types.
Decision tree classifier
We used a nearest centroid decision tree classifier to
assign to each breast cancer a cell-type subpopulation
according to how similar their tumour profile is to each
of the cell centroids. To achieve this assignment we
used a decision tree. First, each tumour was assigned to
either the stromal, basal, luminal or LP centroid using
the nearest centroid rule on the Pearson correlation
scores. If a sample classified according to the LP type,
we then assigned it to a further LP subtype using the
nearest centroid rule against the correlation scores com-
puted from the individual LP subtype-specific centroids.
Statistical analysis
Data presented are the mean of multiple independent
experiments and the standard error of the mean. One-
way analysis of variance was used to test multiple
groups followed by Tukey’s post test to test significant
differences between pairs of results. Comparisons
between just two groups were analysed by Student’s t
test. Significance was set at * = P < 0.05, ** = P < 0.01
or *** = P < 0.0001.
Results
Two distinct luminal progenitor cell types exist within the
mouse mammary epithelium
To test the hypothesis that the LP population is a het-
erogeneous population, we dissociated mammary glands
from 10-week-old virgin C57BL6/J females and analysed
the liberated cells using flow cytometry to detect
EpCAM, and CD49f (a6-integrin; Figure 1A and Addi-
tional file 2A). We used EpCAM rather than the pre-
viously described CD24 [8,9] since the use of EpCAM
permits greater resolution of the luminal and basal cell
subpopulations. We also used CD49b (a2-integrin)
instead of CD61 (b3-integrin) to identify LPs. We
observed that CD49b+ was a more selective marker of
LPs than the previously reported CD61 [26] since up to
47% of progenitors are of CD61- phenotype (Additional
file 4A,B).
As shown in Figure 1A, the luminal cell compartment
can be subdivided into three distinct subpopulations on
the basis of expression of CD49b and Sca1. We
observed a fourth population (Sca1-CD49b-) during
pregnancy and remnants of this population are main-
tained throughout the involution and post-involution
stages (region gates R9 and R7 in Figure 1B; see Addi-
tional file 4C). Flow sorting the three subpopulations
from the virgin gland and seeding them into two-dimen-
sional colony-forming cell (CFC) assays reveals that pro-
genitor activity is restricted to the Sca1-CD49b+ and
Sca1+CD49b+ subpopulations (Figure 1C). Cloning
efficiency was observed to be approximately 25% and
40% for Sca1+CD49b+ and Sca1-CD49b+ progenitors,
respectively. However, we suspect that these cell popula-
tions may be pure progenitor cells, since flow-associated
toxicity is calculated to be as high as 75% (Additional
file 4D).
Previously, gene expression profiling of sorted mouse
mammary epithelial cells identified CD14, a co-receptor
for bacterial lipopolysaccharide, as being highly enriched
in the luminal cell population [8]. When we examined
the distribution of CD14 expression among the luminal
population, we observe that approximately 86% of LP
cells express this protein, whereas CD14- luminal cells
are relatively deficient in CFCs (Additional file 4E,F,G).
Other studies have reported that c-Kit expression identi-
fies both ER- and ER+ LPs [15] and progenitors that are
primed to generate progeny that can synthesise milk
proteins [16]. When examining c-Kit expression in lumi-
nal cells, we observed variation between mouse strains,
with c-Kit expression localised to a minority of Sca1+
luminal cells, and only in FVB mice (Additional file 4H).
However, we were unable to observe any significant
expression of c-Kit among the luminal cells isolated
from C57BL6/J mice, even when using the same c-kit
antibody clone (2B8) that was previously used [15]. The
c-kit expression levels in FVB mice in our study were
quite low when compared with the other studies; one
explanation for this discrepancy may be the use of dif-
ferent tissue dissociation protocols.
Immunostaining of sorted populations reveals that
both the Sca1+CD49b- and Sca1+CD49b+ cells express
high levels of luminal differentiation markers such as ER
and keratin (Krt)18 compared with the Sca1-CD49b+
cells (Figure 1D,E). These results demonstrate that there
are two functionally distinct types of ER cells in the
mammary gland; the vast majority are relatively mature
with little proliferation capacity, but a small population
representing ~9% of all luminal cells are ER+ progeni-
tors. The ER+ progenitors (Sca1+CD49b+) express higher
transcript levels of luminal differentiation transcripts
such as ER, FoxA1 and Gata3 and lower levels of Krt5
and Krt14 when compared with Sca1-CD49b+ cells (Fig-
ure 1F). Immunostaining of Sca1-CD49b+ (ER-) cells
demonstrates that these cells express lower levels of
Krt18 and low but detectable levels of the basal cell-spe-
cific Krt5 (Figure 1D,E). These cells express no to low
levels of ER, which is in agreement with a previously
published report [17]. This intermediate level of expres-
sion for both luminal and basal cell markers suggests
that these cells are a progenitor cell intermediate
between the basal stem cells and the more differentiated
ER+ LPs.
The ER- progenitor subpopulation also has relatively
higher levels of milk protein transcripts in the virgin
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Figure 1 Mouse luminal compartment contains distinct subpopulations. (A) Distribution of epithelial cell adhesion molecule (EpCAM) and
CD49f among Lin- cells resolves the luminal and basal cell subpopulations (left). Expression of Sca1 and CD49b among the luminal cells resolves
three subpopulations (middle), whose morphology can be visualised using the Image Stream™ analyser (Merck Millipore, Watford, Hertfordshire,
UK) (right). (B) Expression of Sca1 and CD49b in pregnant (left; R9 gate) and 6 weeks post involution (right; R7 gate) mammary glands indicating
the emergence of a fourth luminal cell population. (C) Bar chart showing the distribution of colony-forming cells (CFCs; top) and cloning efficiencies
(middle) of the three luminal populations. Images of CFCs indicating only CD49b+ cells can form colonies (bottom). (D) Immunocytochemical and
immunofluorescence analysis of mouse luminal subpopulations. Cells were sorted, fixed onto slides and stained to detect oestrogen receptor (ER),
keratin (Krt)18, Krt14 and Krt5. (E) Bar chart showing the percentage positive cells for each population. (F) Gene expression analysis of Sca1-CD49b+
and Sca1+CD49b+ populations relative to the comparator (Sca1+CD49b-) for luminal and basal transcripts. Error bars for all indicate the standard
error of the mean for six independent experiments. *P < 0.05, **P < 0.01, ***P < 0.0001. Scale bars = 10 μm.
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state compared with the ER+ progenitor cells, including
a-lactalbumin (Lalba) and milk fat globule-epidermal
growth factor 8 (Mfg-e8), an observation consistent with
previous reports [17]. These cells also express high
levels of Elf5 and Lmo4, both of which have been
involved with specifying alveolar cell fate (Figure 1F)
[18,27]. These results suggest that ER- cells probably
represent alveolar progenitors and are primed for milk
production.
ALDH is an enzyme family previously reported to
identify human mammary stem cells [28]. When we
examined ALDH among the mammary cell populations,
we observed that all of the ER- and a subset of the ER+
LPs show high levels of enzyme activity, whereas the
basal cells (EpCAMloCD49fhi) and NCL (Sca1+CD49b-)
ER+ cells show low or absent activity (Additional file 4I).
Luminal cell population in the mouse mammary gland is
relatively deficient in mammary repopulating units
Previous studies have demonstrated that mammary stem
cells are localised within the basal cell compartment of
the mouse mammary epithelium since MRU-enriched
populations have a basal cell-signature [8,9]. However, a
recent report has challenged the notion that basal cells
are the most potent stem cells since a subpopulation of
MRUs expressing high levels of the luminal cell differen-
tiation marker CD24 can be also be detected [29]. To
investigate this further, we double sorted the three lumi-
nal cell subpopulations to ensure purity and minimise
contamination from other cell types (Additional file 5)
and transplanted them into 25% Matrigel at limiting
dilutions into cleared mammary fat pads of recipient
mice. As shown in Figure 2A, MRUs are present within
the luminal population, albeit at exceedingly low fre-
quencies. No robust MRUs could be detected in the
NCL cells, although occasional small ductal-lobular
structures could be detected at very low frequencies
(Figure 2A,B). Outgrowths derived from these LPs are
morphologically normal and contain all of the subpopu-
lations as those derived from basal cells, although a
skewing in the distribution of luminal and basal cell
populations towards the basal cells is observed when
analysed by flow cytometry (Figure 2B; see Additional
file 6A). Secondary transplantations reveal that four of
the six primary outgrowths contained >5 MRUs, indicat-
ing that some of the luminal MRUs are potent and have
extensive self-renewal capacity and can generate normal
glands (Additional file 6B,C). However, when the distri-
bution of MRUs among all of the mammary cell popula-
tions is calculated, we observe that approximately 99%
of all MRUs present in a mouse mammary gland are
localised within the basal cell population (Figure 2A).
Van Keymeulen and colleagues previously demonstrated
that flow-sorted luminal cells can contribute to the
luminal epithelium upon transplantation into cleared
mammary fat pads, but only when co-transplanted with
an approximate equivalent number of basal cells [10].
To determine which luminal cell population has this in
vivo engrafting potential, double-sorted GFP+ luminal
populations (ER- progenitors, ER+ progenitors and NCL
cells) were mixed with equal numbers of wild-type total
mammary epithelial cells such that the final ratio of
GFP+ marked luminal cells to wildtype basal cells was
approximately 2:1 (Additional file 7). These cell mix-
tures were then transplanted into cleared mammary fat
pads of NSG mice. Outgrowths containing GFP+ cells
could be obtained for all mammary luminal cell popula-
tions, although, like the transplants described in Figure
2A, the frequency of this event was rare since only 1 in
30,000 to 340,000 sorted GFP+ luminal cells could
engraft (Additional file 7). Unlike the previous report by
Van Keymeulen and colleagues, the outgrowths gener-
ated in these experiments were not lineage-restricted
since the engraftments contained both basal and luminal
cells that expressed GFP (Additional file 8). Interest-
ingly, when GFP+ cells engrafted, no engraftment by the
co-injected wildtype basal and luminal cells was
observed, even when nonlimiting numbers of basal cells
were transplanted (Additional file 7). Further work is
required to reconcile these two studies.
Mouse mammary epithelial cells are developmentally
plastic
In an attempt to establish parent-progeny relationships
between the different populations described in Figure
1A, we sorted the different luminal cell populations and
seeded them into in vitro and in vivo assays. When ER-
and ER+ progenitor cells are seeded into three-dimen-
sional Matrigel cultures and maintained for 3 weeks, we
observed that the ER- progenitors generated translucent
alveolar-like structures that contained eosinophilic mate-
rial in the lumen, whereas the ER+ progenitors gener-
ated alveolar-like outgrowths that were optically dense
without any deposits (Additional file 6D). These results
demonstrate that these two types of progenitors are
functionally distinct. However, when these colonies were
examined for expression of lineage markers such as
Muc1 and p63, we observed that both progenitors can
generate colonies that contain both luminal and basal
cell lineages (Additional file 6D). When double-sorted
ER- and ER+ LPs were seeded within collagen/Matrigel
gels or in 100% collagen gels and transplanted under the
renal capsule of NSG mice, both populations generated
outgrowths that contained both luminal (Muc1+ER+)
and myoepithelial (Sma+p63+) cells in virgin mice and
b-casein+ cells in pregnant mice (Figure 2C; see Addi-
tional file 9A). These outgrowths in virgin mice also
contained MRUs since cells dissociated from these renal
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Figure 2 Mouse luminal progenitors have multilineage differentiation potential but a rare mammary repopulating unit potential. (A)
Double-sorted oestrogen receptor-negative (ER-) progenitors, oestrogen receptor-positive (ER+) progenitors and nonclonogenic luminal (NCL) ER
+ cells were injected at the indicated numbers into cleared fat pads and the mammary repopulating unit (MRU) frequency and distribution in
each subpopulation was determined. *Basal MRU frequency is from Prater MD, Petit V, Russell IA, Giraddi R, Menon S, Schulte R, Deugnier M-A,
Glukhova MA and Stingl J (manuscript submitted). (B) Representative whole mounts of outgrowths derived from the different luminal cell
populations (upper panels). Representative primary outgrowths of H & E and immunostained sections to detect luminal (GATA3 and MUC1) and
basal (K5 and p63) cells (lower panels). Scale bar = 100 μm and 10 μm, respectively. (C) Phenotype of colonies generated when ER- and ER+
progenitors are cultured in Matrigel. Scale bar = 10 μm.
Shehata et al. Breast Cancer Research 2012, 14:R134
http://breast-cancer-research.com/content/14/5/R134
Page 8 of 19
grafts could engraft multiple cleared mammary fat pads
(Additional file 9B).
As a further check for high-fidelity sorting, donor cells
(GFP- or GFP+) were mixed with genetically tagged
(GFP+ or GFP-) cells (Additional file 9C) and the geno-
type of the resultant outgrowths was checked by immu-
nohistochemistry for GFP (Additional file 9D). The
outgrowths generated were positive for both luminal
and basal markers and expressed the appropriate geno-
type (Additional file 9D,E). These results demonstrate
that ER+ LPs have the potential to dedifferentiate to
MRUs.
ER+ luminal progenitors are relatively insensitive to loss
of oestrogen and progesterone
Both luminal and basal cells, and particularly mammary
stem cells, were previously reported to be susceptible to
withdrawal of oestrogen and progesterone [30]. To
investigate the effects of oestrogen and progesterone
withdrawal on the different subtypes of mammary lumi-
nal cells, 8-week-old C57BL6/J were ovariectomised and
the change in the number of different mammary cell
types was determined 3 weeks later.
The NCL cells were acutely sensitive to loss of oestro-
gen since the size of these populations decreased by
72%, with the proportion of these cells to total epithelial
cells decreasing in ovariectomised mice when compared
with sham-operated mice (Figure 3A,B,C). The basal,
ER- progenitor and ER+ progenitor subpopulations were
all mildly sensitive to the withdrawal of oestrogen,
decreasing by 46%, 47% and 37%, respectively (Figure
3A,B); no statistically significant effect was observed
with any of the luminal populations. When the CFC
content from ovariectomised and sham-operated mice
was analysed, the ER- progenitor population in ovariec-
tomised mice contained 31% fewer progenitors than
control mice, and the colonies that were generated were
smaller (Figure 3D,E). The number and size of the resul-
tant colonies derived from ER+ progenitors isolated
from ovariectomised mice were marginally smaller when
compared with controls, although these differences were
not statistically significant. No effect of ovariectomy was
observed on any of the non-epithelial (EpCAM-CD49f-
and EpCAM-CD49f+) cell populations.
These results demonstrate that all populations of
mammary epithelial cells are sensitive to loss of steroid
hormones, but the ER+ LPs are only mildly affected and
have a survival advantage when compared with the
other epithelial cell populations.
Luminal progenitor compartment in human mammary
gland is composed of three distinct cell types
Previous studies have demonstrated that the luminal
compartment in the human mammary epithelium can
be divided into a luminal-restricted progenitor popula-
tion (EpCAM+CD49f+) and mature NCL (EpCAM
+CD49f -) cells that express high levels of ER [31,32]. To
test the hypothesis that this LP cell compartment is het-
erogeneous, as in the mouse, we screened the expression
of a variety of markers in 11 reduction mammoplasty
samples using flow cytometry. We observed that the dif-
ferential expression of ALDH and ERBB3 was able to
resolve the LP population into not two but three subpo-
pulations of cells: ALDH+ERBB3+ (ALDH+), ALDH-
ERBB3+ (ALDH-) and ALDH-ERBB3- (ERBB3-) (Figure
4A; see Additional file 2B,C - the threshold between
ALDH- and ALDH+ is set with reference to a control
population incubated in the presence of ALDH inhibitor
DEAB, whilst ERBB3 gating was determined using FMO
controls). The proportion of these subtypes of cells is
very variable between different donors, especially the
ERBB3- subpopulation, which can range in frequency
from 2 to 65% of the total LP population (Figure 4B).
However, only one-quarter of all patients have a dis-
tinctly identifiable ERBB3- population (Figure 4A, mid-
dle and lower panels). This population appears to have
no correlations with age, although other clinical para-
meters such as parity, menstrual stage and oral contra-
ceptive use are not known.
All three subpopulations express the luminal-specific
KRT8; they also express KRT5 but not KRT14 (Figure
4C). These latter two keratins have historically been
considered specific for basal cells, although a recent
report has challenged this notion [33]. Gene expression
analysis by quantitative RT-PCR confirms that ALDH
expression is highest in the ALDH+ population and low-
est in the NCL cells (Figure 4D). When we examine the
distribution of the luminal differentiation markers
MUC1, AR and FOXA1 among the luminal cell popula-
tions, we consistently observe that the ERBB3- popula-
tion displays the lowest levels of luminal differentiation,
followed by ALDH+, with ALDH- and NCL cells display-
ing the highest levels of luminal differentiation (Figure
4D) - with the exception being that ALDH+ cells express
the highest levels of MUC1 protein (Additional file
10A). Transcripts for ER and GATA3 are not signifi-
cantly different in the NCL and ALDH- subpopulations
when compared with the ERBB3- and ALDH+ subpopu-
lations. The ERBB3- LPs express the highest levels of
the basal-specific genes KRT14, myosin light chain
kinase and snail homolog 2a and lower levels of the
luminal marker KRT19 when compared with the other
LP populations. Interestingly, the ALDH+ subpopulation
expresses the highest levels of transcripts for ELF5,
MFG-E8 and LFT (lactoferrin), thereby suggesting that
these cells are primed for milk production (Figure 4D).
It has previously been reported that human breast
cancer stem cells often have an EpCAM+CD44+CD24-/
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Figure 3 Influence of ovariectomy on mouse mammary epithelial cell subpopulations. (A) Flow cytometric analysis showing the
distribution of epithelial and non-epithelial cell types from control and ovariectomised (Ovx) mice. (B) Bar chart depicting total epithelial cell
numbers in control and Ovx mice. (C) Proportion of epithelial cell populations in control and Ovx mice. (D) Total colony-forming cell (CFC)
numbers in control and Ovx mice. (E) Size of colonies generated from oestrogen receptor-negative (ER-) and oestrogen receptor-positive (ER+)
progenitors isolated from control and Ovx mice. Right panels: CFCs of a representative experiment. Error bars indicate the standard error of the
mean for four independent experiments. *P < 0.05, **P < 0.01, ***P < 0.0001. EpCAM, epithelial cell adhesion molecule; NCL, nonclonogenic
luminal.
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Figure 4 Three distinct luminal progenitors exist in the human mammary gland. (A) Left: distribution of CD49f and epithelial cell adhesion
molecule (EpCAM) in the Lin- population from three patients. Right: distribution of aldehyde dehydrogenase (ALDH) and ERBB3 in the luminal
progenitor subset. (B) Summary of distribution of luminal progenitor populations and the age of the patients. (C) Expression of keratin (KRT)8,
MUC1, KRT5 and KRT14 among the three luminal progenitor populations. (D) Gene expression analysis of ALDH+, ALDH- and ERBB3-
subpopulations relative to the comparator populations (nonclonogenic luminal (NCL)) for oestrogen receptor (ER), KRT14, MFG-E8, epidermal
growth factor receptor (EGFR), GATA3, ERBB2, MUC1, ALDH1A3, LFT, AR, DACH1, ELF5, FOXA1, KRT19, myosin light chain kinase (MYLK), PR and
snail homolog 2a (SNAI2A). (E) Frequency and distribution of colony-forming cells (CFCs) among the three luminal progenitor populations. (F) H
& E and immunostained sections of xenograft gels derived from ALDH+, ALDH- and ERBB3- progenitors. Shown is the expression of MUC1,
GATA3, SMA, p63, ER and prolactin-induced protein (PIP) among outgrowths. All error bars indicate the standard error of the mean from at least
five independent samples. *P < 0.05, **P < 0.01, ***P < 0.0001. Scale bars = 10 μm.
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low phenotype [34]. To understand the normal cellular
context of this signature, we used flow sorting to deter-
mine the distribution of CD24 and CD44 among the dif-
ferent human mammary epithelial cell populations
described in Figure 4A. Our results demonstrate that
none of the luminal cell populations have this pheno-
type and that this phenotype is restricted only to the
basal cell population (Additional file 10B,C).
To interrogate the proliferative capacities of the three
different LP populations, purified cells from each popu-
lation were seeded into CFC assays. Results demonstrate
that the ALDH+ subpopulation had the highest cloning
efficiencies and contained the highest proportion of
CFCs (Figure 4E). Surprisingly the ERBB3- population
had a very low cloning efficiency and contained an
almost undetectable number of progenitor cells, which
was unexpected since these cells have a relatively undif-
ferentiated phenotype.
These results demonstrate that the ALDH+ subpopula-
tion in the human mammary gland is analogous to the
ER- population in the mouse because both populations
contain the highest proportion of progenitors and
express high levels of ALDH1a3 and alveolar-associated
genes (Figures 1C,F and 4D,E; see Additional file 4F).
Normal human mammary epithelial cells are
developmentally plastic
To further characterise the growth and differentiation
potential of the three LPs, we sorted these cells and
seeded them into collagen gels that were then trans-
planted under the renal capsule of female NSG mice.
All three subpopulations have the ability to generate
hollow acinar multilayered structures (Figure 4F), albeit
with vastly different efficiencies since the ERBB3- sub-
population generated very few outgrowths. All three
LPs gave rise to engraftments that contained both
luminal (MUC1+GATA3+) and basal (p63+SMA+) cells
(Figure 4F). Some engraftments from all populations
generated single-layered structures that only contained
luminal cells (Additional file 11A). Both ALDH- and
ERBB3- progenitors could generate both ER+ and ER-
cells (Figure 4F). The ALDH+ cells, despite being able
to generate GATA3+ cells, were unable to generate ER
+ cells during the initial 5-week assay. However, ER+
progeny could be detected when the assay was
extended for an additional 3-week period, thereby sug-
gesting that ALDH+ cells are a primitive progenitor
cell that needs additional time to generate all cell
lineages (Additional file 11B). A similar pattern of
expression was observed when the grafts were exam-
ined for expression of prolactin-induced protein, a pro-
tein whose expression occurs in the majority of ER+
breast tumours [35]. Both ALDH- and ERBB3- progeni-
tors could generate prolactin-induced protein positive
progeny, whereas ALDH+ cells were unable to do so
during the 5-week assay (Figure 4F).
ALDH+ luminal progenitors have a gene signature similar
to that obtained from basal-like breast cancers
The LP population has previously been shown to have a
gene expression signature resembling that of basal-like
breast tumours, while the NCL cells resemble Luminal
A/B tumours [32]. We hypothesised that subdividing the
LP population would identify a closer relationship
between the different types of mammary epithelial cells
and the different breast cancer subtypes.
To test this hypothesis we sorted six different freshly
isolated mammary cell populations (NCL, ALDH-,
ALDH+, ERBB3-, basal and stromal) isolated from up to
11 mammoplasty samples and obtained gene expression
profiles of these cells (Additional files 12 and 13). As
expected, all three LP populations had gene profiles
more similar to basal-like breast cancers than the other
sorted breast cell populations (Figure 5A; see Additional
file 14). Although the gene signature from the ALDH-
population most strongly correlates with basal-like can-
cers, it also has some correlations with the Luminal A
and B signatures (Figure 5A). When we created a deci-
sion tree for the different luminal subpopulations, how-
ever, we observed that the gene signature of the ALDH+
population, and not the ALDH- or ERBB3- subpopula-
tions, had the highest correlation with those obtained
from basal-like breast tumours (Figure 5B). Consistent
with what was previously reported, the gene expression
signature of the NCL cells resembled those obtained
from Luminal A/B breast cancer subtypes and the stro-
mal cells resembled the claudinlow subtype (Figure 5A)
[32]. To obtain a broader picture of the molecular char-
acteristics of the different mouse mammary epithelial
cell subpopulations, gene expression profiles of these
cells were obtained. Results showed that the gene signa-
tures of each luminal cell population are unique and
distinct from basal cells (Figure 5C; see Additional file
15). Similar observations are seen when the microarray
expression profiles of the purified mouse mammary cell
populations are compared with those obtained from
human breast tumours since the ER- LPs have a gene
expression profile that most resembles that of human
basal-like breast tumours and the NCL ER+ cells resem-
bling Luminal A/B tumours (Figure 5D).
Discussion
The results presented here demonstrate that the luminal
cell compartment in both the human and mouse mam-
mary glands is much more heterogeneous than initially
perceived since progenitors of varying levels of luminal
cell differentiation can be identified and prospectively
isolated. In the mouse, these populations resolve as
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separable ER+ and ER- subpopulations, whereas in the
human the ALDH+ and ALDH- subpopulations appear
to comprise a larger contiguous population. The cell
types of the different species appear to be homologous
to one another; for example, the ER- LPs in the mouse
are equivalent to the ALDH+ cells in the human, and
likewise for the ER+ luminal mouse progenitors and the
ALDH- luminal human progenitor cells because both
populations collectively express higher levels of luminal
cell differentiation markers than the ER-/ALDH+ subpo-
pulations. The ER+ cells in the mouse are probably duc-
tal-restricted progenitors since they express higher levels
of ER and FoxA1, transcription factors that have been
demonstrated to be essential for ductal but not lobular
morphogenesis during mammary gland development
[36]. A similar distribution of FOXA1 is also observed
in human ALDH- cells, thereby suggesting that these
cells function as ductal progenitors in the human mam-
mary gland. Likewise, the ER- progenitor cells identified
in the mouse mammary gland appear to be alveolar pro-
genitors since they express high levels of Elf5 and Lmo4,
transcription factors that specify alveolar cell fate
[18,27], as well as milk components including Lalba and
Mfg-e8 [37]. In the homologous human population,
ALDH+ cells express high levels of ELF5 and the milk
proteins MFGE8 and LFT, which supports the concept
that these cells represent a pool of progenitors that are
primed to generate alveoli during pregnancy.
Our results demonstrate that there are two types of
ER+ cells in the mammary epithelium; most have little
or no proliferative potential and thus are interpreted as
being relatively mature, but a small population of ER+
progenitors can be identified and prospectively isolated.
Whether these ER+ progenitors give rise to the mature
Figure 5 Comparison of normal mammary cell populations with breast cancer molecular subtypes. Aldehyde dehydrogenase-positive
(ALDH+) and oestrogen receptor-negative (ER-) progenitors have a gene expression profile similar to basal-like breast cancers. (A) Boxplots
depicting correlation scores of ALDH+ (A+), ALDH- (A-), ERBB3- (E-), nonclonogenic luminal (NCL; L), basal (B) and stromal (S) cell subtypes,
stratified according to breast cancer intrinsic subtype. (B) Results of the decision tree nearest-neighbour classifier showing the relation between
cell-type-specific signatures and those defining the breast cancer intrinsic subtypes. The ALDH+ subpopulation scores the highest with regards to
similarity to the basal-like breast cancer signature. (C) Heatmap of genes (red, high expression; green, low expression) of the top 5% differentially
expressed genes in the four types of mouse mammary epithelial cells. Samples are clustered on the basis of cell type. (D) Boxplots depicting
correlation scores of intrinsic subtypes stratified according to mouse mammary cell subtype.
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ER+ luminal cells is not known; in vivo lineage tracing
experiments using an ER+ progenitor-specific promoter
will need to be performed to establish the developmen-
tal relationships between these two cell types.
Results presented herein demonstrate that ER+ pro-
genitor cells, at least in the normal mouse mammary
gland, appear to have a selective advantage over the
other mammary epithelial cell populations in adapting
to a low-oestrogen environment. ER expression levels in
individual mammary epithelial cells are inversely corre-
lated to circulating oestrogen levels [38,39], and thus we
hypothesise that the low-oestrogen environment pro-
motes high levels of ER expression and skews the LP
pool from an ER- state to an ER+ state. Whether there
is a similar preferential survival of ER+ LP cells in the
human breast after menopause is not known, although
histological studies comparing premenopausal and post-
menopausal women report an increase in the frequency
of total ER+ cells and proliferating ER+ cells within the
postmenopausal mammary gland [40,41]. Garbe and col-
leagues recently reported that there is an enrichment of
LP cells within the mammary epithelium with advancing
age. However, these LPs were skewed to a more basal
phenotype, which is at odds with our results describing
an enrichment of a more luminal type of progenitor
[42].
Both oestrogen and progesterone can influence the
proliferation of ER-/PR- cells in the mammary epithe-
lium via paracrine factors such as amphiregulin, Wnt-4
and RANK ligand [30,43-47]. Progesterone can directly
promote the proliferation of PR+ cells via upregulation
of cyclin D1 and cyclin D2 [47]. Evidence also suggests
that oestrogen can directly promote the proliferation of
ER+ cells in the normal mammary gland since recruit-
ment of ER+ cells into the cell cycle is maximal when
circulating oestrogen levels are highest [48]. These ER+
progenitors are of interest because they represent a
potential target cell for malignant transformation. ER+
cells are typically distributed within the normal mam-
mary epithelium as single cells, but in atypical ductal
hyperplasia and ductal carcinoma in situ the ER+ cells
tend to be clustered as contiguous islands, suggesting
clonal expansion of a mutated ER+ precursor cell. The
frequency of proliferating ER+ cells in these islands of
cells is positively correlated with breast cancer risk,
again suggesting that these ER+ cells are precursors for
invasive breast lesions [41].
The hypothesis that postmenopausal breast cancer ori-
ginates in undifferentiated (ALDH-) progenitors does
not fit with the fact that these tumours are predomi-
nantly of the Luminal A/B subtypes because the ALDH-
progenitors described herein have highest correlation
with basal-like cancers. One possible explanation for
this discrepancy is that tumours may originate in an
ALDH- progenitor population, but these cells than dif-
ferentiate to produce mature ER+ progeny that have a
Luminal A/B signature. Another possible explanation is
that all of the gene signatures obtained for this study
were obtained from premenopausal women (mean age
33.6 years), and that a gene signature of an ALDH- cell
in the postmenopausal state could be different (for
example, more Luminal A/B-like) than those obtained
from premenopausal women. More work in determining
the role of these cells in breast cancer progression is
clearly required.
ERBB3 is a member of the epidermal growth factor
receptor family and often forms heterodimers with
ERBB2 [49]. ERBB3 is overexpressed in approximately
22% of breast cancer cases [50], and 25% of cases are
reported as being ERBB3-negative. The ERBB3- LPs in
the human mammary gland are somewhat unusual since
they have an intermediate phenotype between luminal
and basal cells, but appear to be deficient in growth
potential. Currently unknown is why only one-quarter
of patient samples contain this subpopulation and why,
when present, the size of this population is so variable.
There is no apparent correlation with the age of the tis-
sue donor in the small sample set analysed here. At the
time of collection of these tissue samples no information
was available regarding parity history, menstrual cycle
status and oral contraception use. Further studies with a
much larger well-annotated sample set will be required
to gain an insight into the nature of these cells.
Although the function of these ERBB3- cells is cur-
rently not known, we hypothesise that these cells may
be involved with alveologenesis. In the mouse, ErbB3 is
required, via phosphoinositide 3-kinase signalling, for
the development of the ducts during mammary gland
development, but is not essential for the formation of
lobules during pregnancy [51,52]. Balko and colleagues
reported that ERBB3 expression in the mammary
epithelium is highest in the luminal cell populations and
lowest in the basal cells, and that loss of ErbB3 in the
luminal cell compartment in mice results in an increase
in apoptosis of these cells and an expansion of the basal
cell population via paracrine signalling [53]. Our results
regarding the distribution of ERBB3 among human
mammary luminal cells agree with those described by
Balko and colleagues, although the presence of a subpo-
pulation of cells with a LP phenotype that are ERBB3-
appears to be a novel observation.
We used functional assays to establish the growth and
differentiation potential of the different types of human
and mouse LP cells, and in agreement with the findings
of Keller and colleagues [5] we observed that all types of
freshly isolated LPs in both species display multilineage
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potential when assayed using reconstitution assays,
albeit with different frequencies. Other groups have
reported that luminal cells in both human and mouse
mammary glands can generate multiple lineages of pro-
geny when assayed in vitro [17,54-56]. However, these
latter observations are not consistent with the results
presented here and by Eirew and colleagues [31] since
we observe that the majority of cells with in vivo
engrafting potential are localised within the basal cell
compartment. Part of this discrepancy could be due to
different groups testing for stemness using different
assays. However, the observation that both luminal and
basal cell populations exhibit stem cell properties is con-
sistent with a recent report by Van Keymeulen and col-
leagues. They demonstrate by in vivo lineage tracing
that both the luminal and basal cell compartments in
the mouse mammary gland are maintained by their own
stem cell populations during normal tissue homeostasis
[10]. This study highlights important caveats in inter-
preting the results of reconstitution assays, as the differ-
entiation repertoire of cell populations may be
perturbed when taken out of a normal tissue environ-
ment and purified from other mammary cell types.
Reconstitution assays can also mask stem cell potential
if cells are transplanted in the absence of appropriate
helper cells [10]; this can have obvious limitations when
trying to identify putative cancer stem cell populations.
The transplantation process possibly allows LPs to dis-
play an expanded differentiation repertoire. Additional
work is thus needed to discriminate the growth and dif-
ferentiation potential that may occur outside normal tis-
sue homeostasis from lineage differentiation that occurs
in normal homeostasis. Identifying promoters that are
specific for each of the different luminal cell populations
will be essential so that the identity of the luminal stem
cells and the developmental relationships between the
different luminal cells can be established. Such promo-
ters will also be essential for designing transgenic mouse
mammary tumour models so that the cell of origin for
different molecular types of breast tumours can be
established. Current candidates for cell-specific promo-
ters include CD14 for the entire LP population and Elf5
for the ER- LP population. Promoters that are specific
for the nonclonogenic ER+ cells and ER+ LPs have yet
to be identified.
ALDH has previously been reported to be a marker of
breast stem cells [28]. However, we and others have
observed that ALDH is expressed primarily in the LP
compartment in both humans and mice [57,58]. The
expression pattern of ALDH within the LP compartment
as opposed to the basal stem cell containing compart-
ment clarifies a discrepancy regarding the influence
of the loss of BRCA1 on human epithelial cell
differentiation [59]. Women who have lost an allele of
BRCA1 have smaller basal cell populations and
expanded LP cell populations [32], whereas forced
downregulation of BRCA1 results in the expansion of
the ALDH+ subpopulation, a population initially inter-
preted as being the stem cell population and distinct
from the LP cells [60]. In hindsight, it is now clear that
knockdown of BRCA1 results in expansion of the
ALDH+ LP population. In the human epithelium, the
ALDH- and ALDH+ subpopulations are clearly part of a
larger contiguous population, thereby indicating that
these two subpopulations are developmentally tightly
linked. We observed that an increase in luminal cell dif-
ferentiation exists across this population as ALDH
expression is lost, and thus one could envision that even
low levels of developmental plasticity of an ALDH- cell
to an ALDH+ cell could result in loss of luminal cell
differentiation.
The results presented here suggest that ALDH1a3 is
one of the ALDH isoforms that is being detected by the
Aldefluor substrate. Different ALDH isoforms have been
shown to be important in different types of cancers, but
ALDH1a3 is emerging as a potential cancer stem cell
marker in breast cancer [28,61]. ALDH expression, as
determined by immunohistochemical staining of tissue
sections, has been linked to several breast cancer para-
meters including ER negativity, high histological grade
and general association with basal-like breast cancers
[62,63]. Our results using purified subpopulations of
human breast epithelial cells are in agreement with
these conclusions.
In the context of normal development, therefore, a
model of the mammary epithelial cell hierarchy is pre-
sented in Figure 6. The basal stem cells undergo either
self-renewal or differentiation into a LP (during embryo-
genesis) or a myoepithelial cell. Environmental signals
control commitment of the LP populations to further
differentiate to an ER+ ductal cell or, during pregnancy,
to a milk-producing alveolar cell. In vivo lineage tracing
experiments in mice will need to be performed to vali-
date these developmental relationships.
Conclusion
The results presented in this manuscript demonstrate
that there is more heterogeneity present in the luminal
mammary epithelium of both humans and mice than
initially perceived. LP cells with gene expression pat-
terns consistent with ductal and alveolar progenitors
can be identified and prospectively isolated from both
species, with these latter cells having gene expression
profiles that strongly resemble those obtained from
basal-like breast tumours. The LP compartment in the
human mammary epithelium also contains an additional
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cell population that is characterised by lack of ERBB3
expression and low proliferative potential. The ER+ LPs
in the mouse are unique in that they are relatively
insensitive to loss of oestrogen and progesterone when
compared with the other mammary cell populations;
this may have implications for the incidence of ER+ and
ER- breast cancer in premenopausal women versus post-
menopausal women.
Additional material
Additional file 1: Table S1 presenting antibodies used for
immunostaining: primers used for amplification of p53 isoforms
and actin by RT-PCR (nested PCRs), and antibodies used to stain
the different cell populations. Table S2 presenting SYBR primers used
for quantitative RT-PCR analysis: mouse and human specific primers used
for this study.
Additional file 2: Figure presenting the gating cascade. (A) Gating
strategy for flow cytometric analysis and sorting for mouse mammary
epithelial cells. Cells were gated on forward (FSC) and side (SSC) scatter
to remove debris. Then FSC-W/A and SSC-W/A were selected respectively
to obtain single cells. 4’,6-diamidino-2-phenylindole (DAPI)-positive and
lineage-positive cells were excluded. (B) Gating approach for flow
cytometric analysis and sorting for human mammary epithelial cells. Cells
were gated on FSC and SSC to remove debris. Then FSC-width and SSC
gating were set to exclude doublets. DAPI-positive and lineage-positive
cells were excluded. (C) Representative ALDH FACS profiles of total viable
cell populations. Cells incubated with ALDH substrate (right) or ALDH
and the specific inhibitor DEAB, (left). DEAB controls were used to set the
gating strategy to define the ALDH+ population.
Additional file 3: MIAME checklist detailing the microarray
experimental information.
Additional file 4: Figure showing phenotypic characterisation of
mouse epithelial cell subpopulations. (A) Distribution of CD61 among
luminal cells. (B) Distribution of CD61 among luminal CFCs showing
mean ± standard error of the mean. (C) Proportion of the different
luminal subpopulations in virgin and post-involution mammary cells. (D)
Effects of antibody staining and flow sorting on colony forming
efficiencies. (E) Distribution of CD14 among luminal cells. (F) Distribution
of CD14 and Sca1 among luminal (CD24high) epithelial cells. (G)
Distribution of CD14 and CD24 among luminal CFCs showing mean ±
standard error of the mean. (H) Distribution of c-Kit among luminal cells
in C57BL6/J (upper panel) and FVB mice (lower panel). (I) Flow
cytometric analysis showing the distribution of ALDH among subtypes of
mouse mammary epithelial cells.
Additional file 5: Figure showing the gating strategy for double-
sorting mouse luminal cell subpopulations.
Additional file 6: (A) Flow cytometric analysis to determine the
distribution of the different epithelial cell populations generated
from transplanted ER+ progenitors, ER- progenitors and basal cells.
Figure 6 Proposed epithelial cell hierarchy in the mouse and human mammary glands. Basal stem cells undergo either self-renewal or
differentiation into a luminal progenitor (during embryogenesis) or a myoepithelial cell. Upon certain environmental signals, the luminal
progenitor populations may be able to commit to an oestrogen receptor (ER)-positive ductal cell or, during pregnancy, to a milk-producing
alveolar cell. In vivo lineage tracing experiments in mice will need to be performed to validate these developmental relationships. ALDH,
aldehyde dehydrogenase; EpCAM, epithelial cell adhesion molecule; PR, progesterone receptor.
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(B) Number of secondary outgrowth derived from primary transplants of
ER- and ER+ progenitors. (C) H & E and immunostained sections of
secondary outgrowths. Top panel: H & E section of the entire fat pad
and a zoomed image of the black square. Lower panel: sections from
outgrowths stained to detect Krt14 and Gata3. (E) Morphology of
colonies generated when ER- and ER+ progenitors are cultured in
Matrigel. Scale bars = 10 μm.
Additional file 7: Table presenting the MRU frequency and
distribution in each GFP+ subpopulation determined for double-
sorted ER- progenitors, ER+ progenitors and NCL cells co-injected
with wildtype mammary epithelial cells at the indicated numbers
into cleared fat pads.
Additional file 8: Figure showing luminal cells have multilineage
potential. Flow analysis to determine the genotype and distribution of
the different epithelial cell populations generated from co-transplanting
wildtype mammary cells and (A) GFP+ ER- progenitors, (B) GFP+ ER+
progenitors and (C) GFP+ NCL cells. Far right: GFP+ outgrowths of the
initial cell population. Scale bars = 100 μm.
Additional file 9: Figure showing both ER- and ER+ luminal
progenitors can have multilineage potential. (A) Expression of ER,
p63, Krt5 and Muc1 among renal graft outgrowths generated in 100%
collagen gels. (B) Representative whole mounts of outgrowths generated
from ER- and ER+ luminal progenitors initially propagated as subrenal
transplants then transplanted into cleared mammary fat pads. Subrenal
grafts were dissociated into single cells and all cells injected into the
cleared fat pad of secondary recipient mice. Scale bar = 100 μm. Right:
bar chart showing the percentage of the fat pad filled by outgrowths 6
to 8 weeks post transplantation (n = 4). (C) Schematic illustration of GFP
+/- purity check. (D) Representative sections of renal grafts derived from
different progenitor types immunostained to detect GFP. (E)
Immunofluorescence staining of renal grafts derived from GFP+ donor
cells. Sections stained with antibodies to detect Krt5, ER, p63, Muc1, Sma
and Gata3.
Additional file 10: Figure showing distribution of (A) MUC1, (B)
CD24 and (C) CD44 among human mammary epithelial cell
subtypes.
Additional file 11: Figure showing immunohistochemistry of
xenograft gels derived from ALDH+, ALDH- and ERBB3- progenitors
for (A) p63 expression and (B) ER expression in engraftments >8
weeks. Some outgrowths generated from all populations do not contain
basal cells. Scale bars = 10 μm.
Additional file 12: Dataset for microarray centroids of purified
human mammary cell populations.
Additional file 13: Dataset for microarray centroids of purified
human luminal progenitor cells.
Additional file 14: Figure showing boxplots depicting correlation
scores of ALDH+ (A+), ALDH- (A-), ERBB3- (E-), NCL (L), basal (B) and
stromal (S) cell subtypes, stratified according to breast cancer
intrinsic subtype from another two cancer datasets: (A) Fridlyand
and colleagues [64], and (B) Schmidt and colleagues [65].
Additional file 15: Dataset for microarray centroids of purified
mouse mammary cell populations.
Abbreviations
ALDH: aldehyde dehydrogenase; AF: Alexa Fluor; CFC: colony-forming cell;
DMEM: Dulbecco modified Eagle’s medium; EpCAM: epithelial cell adhesion
molecule; ER: oestrogen receptor; FBS: foetal bovine serum; GFP: green
fluorescent protein; H & E: haematoxylin and eosin; Krt: keratin; LP: luminal
progenitor; MRU: mammary repopulating unit; NCL: nonclonogenic luminal;
NSG: NOD/SCID IL2Rγc-/-; PCR: polymerase chain reaction; RT: reverse
transcriptase.
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